Showing 1-7 of 7 resultados for "SML1750"
Irina Artsimovitch et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 55 Suppl 2, S127-S131 (2012-07-07)
Fidaxomicin was recently approved for the treatment of Clostridium difficile infection. It inhibits transcription by bacterial RNA polymerase. Because transcription is a multistep process, experiments were conducted in which fidaxomicin was added at different stages of transcriptional initiation to identify...
Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin.
Maxime Gualtieri et al.
Antimicrobial agents and chemotherapy, 50(1), 401-402 (2005-12-27)
A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin.
Tannock G W, et al.
Microbiology, 156(11), 3354-3359 (2010)
M S Osburne et al.
Journal of virology, 33(3), 945-953 (1980-03-01)
We have used lipiarmycin, a specific inhibitor of initiation of transcription, to study the role of host RNA polymerase in the transcription programs of various phages of Bacillus subtilis. Unlike rifampin, lipiarmycin preferentially inhibits transcription dependent on the sigma subunit...
Alan P Johnson
Current opinion in investigational drugs (London, England : 2000), 8(2), 168-173 (2007-03-03)
Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum, for the potential treatment of Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infection. A phase IIb/III clinical...
M M Wösten
FEMS microbiology reviews, 22(3), 127-150 (1998-11-18)
The initiation of transcription is the most important step for gene regulation in eubacteria. To initiate transcription, RNA polymerase has to associate with a small protein, known as a sigma-factor. The sigma-factor directs RNA polymerase to a specific class of...
Farah Babakhani et al.
Antimicrobial agents and chemotherapy, 58(5), 2934-2937 (2014-02-20)
Fidaxomicin (FDX) is a narrow-spectrum antibiotic for the treatment of Clostridium difficile-associated diarrhea. While FDX and rifamycins share the same target (RNA polymerase), FDX exhibits a unique mode of action distinct from that of rifamycins. In comparative microbiological studies with...

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.